All news from R&D

Early Clinical Trial Access: Barriers Still Exist

Young cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congress in Munich, you have highlighted the existence of barriers to the inclusion of 12 to 25-year-olds in both adult and early childhood clinical trials, suggesting a need for more tailored approaches to give this patient population better access to therapeutic innovation.

Cystic fibrosis; New Hope Say Experts

A new triple-combination drug treatment being trialed at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosisMater Research Institute-University of Queensland (MRI-UQ) researcher Dr. Lucy Burr said these patients were enrolled in Phase 2 of the clinical trial, which aimed at treating the underlying cause of cystic fibrosis.

Breast Cancer: Statistical Method Estimates Long- and Short-term Risk of Recurrence

A statistical method could fill the gaps in the US cancer registry data to estimate the short- and long-term risk of recurrence of hormone receptor (HR) -positive and HR-negative breast cancers. 

The study found that while women diagnosed with HR-positive breast cancer have lower risk of progression to metastatic disease soon after the diagnosis, their risk persists for several years. In contrast, for women diagnosed with HR-negative disease, the risk of progression to metastatic disease is high after the diagnosis, but the long-term risk is lower than that for HR-positive disease. The study is published in the journal Cancer Epidemiology, Biomarkers & Prevention